KENNEDY CAPITAL MANAGEMENT LLC - CELLDEX THERAPEUTICS INC NEW ownership

Quarter-by-quarter ownership
KENNEDY CAPITAL MANAGEMENT LLC ownership history of CELLDEX THERAPEUTICS INC NEW
ValueSharesWeighting
Q3 2023$2,405,083
-18.7%
87,394
+0.2%
0.06%
-14.5%
Q2 2023$2,959,646
+1.1%
87,228
+7.2%
0.07%
-19.8%
Q1 2023$2,927,549
-19.2%
81,366
+0.1%
0.09%
-15.7%
Q4 2022$3,624,388
+58.5%
81,319
-0.0%
0.10%
+52.2%
Q3 2022$2,287,000
+248.6%
81,350
+234.6%
0.07%
+272.2%
Q2 2022$656,000
-21.4%
24,316
-0.8%
0.02%
-10.0%
Q1 2022$835,000
-23.3%
24,517
-12.9%
0.02%
-13.0%
Q4 2021$1,088,00028,1580.02%
Other shareholders
CELLDEX THERAPEUTICS INC NEW shareholders Q4 2023
NameSharesValueWeighting ↓
Kynam Capital Management, LP 2,600,000$88,218,00012.13%
Octagon Capital Advisors LP 759,898$25,783,3393.59%
TSP Capital Management Group, LLC 251,895$8,546,8003.08%
ACUTA CAPITAL PARTNERS, LLC 122,343$4,151,0982.81%
5AM Venture Management, LLC 310,270$10,527,4612.62%
COMMODORE CAPITAL LP 631,665$21,432,3932.41%
RTW INVESTMENTS, LP 3,463,201$117,506,4102.24%
Eversept Partners, LP 785,740$26,660,1582.23%
Redmile Group, LLC 1,696,004$57,545,4162.21%
Affinity Asset Advisors, LLC 87,031$2,952,9621.03%
View complete list of CELLDEX THERAPEUTICS INC NEW shareholders